# Gerresheimer account plan

> Gerresheimer is a Düsseldorf maker of drug containment and delivery products for pharma, with FY2025 revenues of EUR 2,320.9m and about 13,600 people.

## At a glance

Gerresheimer AG, based in Düsseldorf, supplies the pharmaceutical, biotech and cosmetics industries with drug containment and delivery products: syringes, pens, auto-injectors, inhalers, injection vials, cartridges, ampoules and plastic and glass bottles. It produces locally in Europe, the Americas and Asia, with companies consolidated from 17 countries and approximately 13,600 people at November 30, 2025. FY2025 (year to November 30, 2025) revenues were EUR 2,320.9m, lifted by the first-time inclusion of Bormioli Pharma, with adjusted EBITDA of EUR 384.0m (16.5% margin) and a net loss of EUR 318.7m. After a BaFin audit led to a restatement of 2024 accounts, the whole Management Board changed; CFO Wolf Lehmann and board member Achim Schalk now lead as co-CEOs pending a permanent CEO.

## Business units

- **Containment & Delivery Systems** (EUR 1,172m 2025 pro forma revenue): Primary Packaging Plastics, Medical Systems and Advanced Technologies: inhalers, insulin pens, auto-injectors, on-body devices and plastic primary packaging. It is the growth engine, with Q3 2026 revenue of EUR 313 million at a 24.5% margin driven by the Peachtree City ramp-up; Centor was sold in October 2026 and the Primary Packaging Plastics sale is expected to close in Q1 2027.
- **Primary Injectable Solutions** (EUR 478m 2025 pro forma revenue): Tubular Glass and Syringe Systems: vials, cartridges, ampoules and prefillable syringes. Q3 2026 revenue was EUR 123 million with a 12.5% margin; Syringe Systems grew while Tubular Glass Europe profitability remains below expectations and is being restructured.
- **Moulded Glass** (EUR 679m 2025 pro forma revenue): Glass bottles, jars and vials for pharma, cosmetics and food and beverage. Q3 2026 revenue was EUR 169 million at a 10.2% margin as inventories were cut; the Chicago Heights plant closed in September 2026, and the unit is run standalone under BU CEO Daniel Winkler ahead of a later divestment.

## Strategic priorities

- **Deleverage and refinance**: Centor closed on October 1, 2026, with about 90% of gross proceeds going to debt and close to EUR 700 million repaid by year-end; after the Primary Packaging Plastics closing, leverage should fall to around 3x and a comprehensive refinancing follow.
- **Grow, fix, sell portfolio**: Grow Medical Device Systems, Syringe Systems and Tubular Glass North America; fix Tubular Glass Europe and SG&A; fix to sell Moulded Glass.
- **Gerresheimer Transformation Offensive (gto)**: Launched September 2025 with five workstreams (Operations, SG&A, Procurement, Commercial Excellence, Cash Management), targeting EUR 50-70 million of annualized EBITDA improvement by end-2027 and full run rate in 2028.
- **Leaner cost base and footprint**: SG&A is to be cut by more than 20% heading into 2027; Bad Königshofen and Chicago Heights are closed and Forest Grove is being merged into Morganton.
- **Drug delivery and GLP-1 growth**: Peachtree revenue is expected to more than double in FY2026 to a triple-digit million euro level, and GLP-1 revenue is in the ballpark of the EUR 350 million target, backed by take-or-pay contracts.
- **Governance clean-up**: The new board completed the bill-and-hold and forensic investigations, increased Internal Audit and Compliance staffing and continues to cooperate with the ongoing BaFin investigation.

## Latest results

Preliminary Q3 2026 (June-August 2026) revenue rose 8% to EUR 605 million, with adjusted EBITDA stable at EUR 103 million (EUR 106 million) and a 17.1% margin (19.0%). Over nine months revenue was flat at EUR 1.7 billion and adjusted EBITDA fell to EUR 272 million (EUR 331 million), hit by inventory reductions and weak Tubular Glass Europe and Moulded Glass. Q3 free cash flow before M&A was EUR -20 million. FY2026 guidance was kept at revenue of EUR 2.3-2.35 billion, an organic adjusted EBITDA margin of 17%-18% and free cash flow of EUR -50 to -100 million, which requires around EUR 120 million of Q4 EBITDA.

## Investments and deals

- **Centor and PPP divestments**: Centor and Primary Packaging Plastics were signed at the end of July 2026 at a combined enterprise value of around EUR 1.5 billion; Centor closed October 1, 2026, PPP is expected in Q1 2027.
- **Drug delivery capacity**: FY2025 capex of EUR 122.7m in Plastics & Devices went to syringe capacity in Germany, Mexico and North Macedonia and plastics and medical systems capacity in North America; FY2026 capex covers injectors and pens in North America and the Czech Republic and syringes at Skopje and Queretaro.
- **Glass furnaces**: FY2025 capex of EUR 177.0m in glass funded new furnaces at Lohr and Momignies and injection-vial capacity at Morganton; FY2026 includes tank rebuilds at Essen and Momignies.
- **Lower capex**: Capex was EUR 149 million in nine months of 2026, 37% lower, about 40% base and 60% growth, and around 9% of sales for the year.

## Challenges and risks

- **Debt and going-concern risk**: Net financial debt was EUR 2,012.9m with leverage of 4.95x at end-FY2025; the auditor's going-concern uncertainty rested on selling Centor and refinancing, and a EUR 100.0m minimum-liquidity covenant applies.
- **Accounting restatement and BaFin**: A BaFin audit over bill-and-hold revenue led to restating 2024 revenue down by EUR 44.6m; the investigation is ongoing with no timeline, and the share was excluded from the SDAX.
- **Weak glass businesses**: Tubular Glass Europe and Moulded Glass remain the problems; Moulded Glass runs at EUR 80-85 million annualized EBITDA against an ambition of EUR 100 million and beyond.
- **Energy costs**: Energy is a substantial cost in glass melting; it is about 80% hedged in 2026 but less than 50% for next year, a headwind for 2027.
- **Lost reverse factoring**: Reverse-factoring lines were withdrawn after a worse credit rating, pushing free cash flow before M&A negative.

## What leadership says

> "This truly marks an inflection point for Gerresheimer, as this solves our too-high-debt burden." — Wolf Lehmann, CFO, On the Centor and PPP sales, preliminary Q2 2026 results call, September 30, 2026

> "The new Gerresheimer will be smaller in size, more focused, and higher in quality" — Achim Schalk, Member of the Management Board, Preliminary Q2 2026 results call, September 30, 2026

> "Clearly, PPG performance is not at an acceptable level." — Uwe Röhrhoff, Interim CEO, FY2025 results call, June 29, 2026

> "our grow, fix, and sell portfolio strategy remains unchanged" — Wolf Lehmann, CFO, Preliminary Q3 2026 results call, October 30, 2026


## Where a supplier can help

- **Procurement and cost programmes**: The gto procurement and operations workstreams and the EUR 50-70 million EBITDA target open the door to suppliers that cut input, logistics or production costs with fast payback.
- **Energy hedging and efficiency**: With less than 50% of next year's energy hedged and glass melting energy-intensive, energy procurement and furnace efficiency solutions tie directly to a stated headwind.
- **Drug delivery ramp-up**: The Peachtree City ramp-up and syringe, injector and pen capacity for GLP-1 customers need automation, quality and validation support.
- **Finance, compliance and controls**: The restatement, BaFin investigation, refinancing and divestments create demand for finance systems, internal controls and carve-out services.
- **Leaner SG&A**: The more than 20% SG&A cut into 2027 suits shared-services, automation and productivity tools.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report 2025 (amended consolidated financial statements)](https://www.gerresheimer.com/fileadmin/user_upload/user_upload/gerresheimer/ir/annual-general-meeting/2026/TOP_1_GB_JA/GB/EN_Gerresheimer_GB_2025.pdf)

Annual report · 2026-07-23

- Gerresheimer is a Düsseldorf-based systems and solutions provider of drug containment and drug delivery products (syringes, pens, auto-injectors, inhalers, vials, cartridges, ampoules, plastic and glass bottles) for the pharmaceutical, biotech and cosmetics industries; about 13,600 people, 49 subsidiaries, companies consolidated from 17 countries.
- FY2025 (year to Nov 30, 2025): revenues EUR 2,320.9m (2024 adjusted: EUR 1,991.3m), driven by the first-time inclusion of Bormioli Pharma (EUR 330.9m); on a pro forma, currency-adjusted basis revenue grew only 0.3%. Adjusted EBITDA EUR 384.0m, margin 16.5% (19.5%); net loss EUR 318.7m; adjusted EPS EUR -1.87; no dividend.
- A year of crisis: a BaFin audit of the 2024 accounts over bill-and-hold revenue (EUR 28m of agreements in Q4 2024) led to a restatement cutting 2024 revenue by EUR 44.6m, the report was delayed to June 2026, the share left the SDAX, and the whole Management Board changed (interim CEO Uwe Röhrhoff, CFO Wolf Lehmann, board member Achim Schalk).
- Heavy write-downs: EUR 167.9m of impairments in Advanced Technologies (mainly Sensile Medical technologies), EUR 50.8m of goodwill in Moulded Glass, EUR 20.5m on Portal Instruments.
- Balance sheet under strain: net financial debt EUR 2,012.9m, adjusted EBITDA leverage 4.95x (2.61x), equity ratio 24.6%; covenants waived through August 2026, 4.75x cap at Nov 30, 2026, EUR 100.0m minimum-liquidity covenant; the auditor's going-concern uncertainty rests on selling Centor Inc. and refinancing.
- New structure from FY2026: Containment & Delivery Systems (2025 pro forma basis EUR 1,172m, 22.9% margin), Primary Injectable Solutions (EUR 478m, 15.3%), Moulded Glass (EUR 679m, 12.8%), the latter to be divested later.
- The Gerresheimer Transformation Offensive (gto), launched September 2025, targets costs, performance and free cash flow over 24 months across five workstreams; Bad Königshofen closed, Chicago Moulded Glass plant closing in 2026.
- FY2026 guidance (June 2026): revenue in the lower half of EUR 2,300m-2,400m, adjusted EBITDA margin about 17%-18%, free cash flow before M&A EUR -50m to -100m (reduced factoring volumes); capex significantly below 2025.

### [Preliminary Q3 and 9M 2026 results: Revenue Growth and Stable Adjusted EBITDA in the Third Quarter of 2026](https://live.deutsche-boerse.com/news/EQS-News-Gerresheimer-Reports-Revenue-Growth-and-Stable-Adjusted-EBITDA-in-the-Third-Quarter-of-2026-35b802dc-2884-4f59-86d7-2ebffe7c7e6c)

Interim report · 2026-10-30

- Preliminary Q3 2026 (June-August 2026): revenue EUR 605 million, up 8% (Q3 2025: EUR 560 million, adjusted); adjusted EBITDA EUR 103 million (EUR 106 million), margin 17.1% (19.0%).
- Nine months: revenue EUR 1.7 billion, flat; adjusted EBITDA EUR 272 million (EUR 331 million), margin 15.9% (19.4%), hurt by inventory reductions and weak Tubular Glass Europe and Moulded Glass.
- Containment & Delivery Systems is the growth engine: Q3 revenue EUR 313 million, adjusted EBITDA EUR 77 million, margin 24.5%, on rising demand for drug delivery devices from newly built capacity.
- Primary Injectable Solutions stabilized: Q3 revenue EUR 123 million, margin 12.5% (16.8%); nine-month margin 9.5% after a weak first half; Tubular Glass restructuring under way.
- Moulded Glass: Q3 revenue EUR 169 million but margin 10.2% (17.4%) as inventories were cut; the Chicago Heights plant closed in September 2026.
- Centor sale completed in October; the Primary Packaging Plastics (PPP) sale is now expected to close in Q1 2027, followed by a comprehensive refinancing.
- A stronger Q4 is expected, in line with guidance; final Q3 figures due December 2026.

### [FY2025 results earnings call (transcript)](https://stockanalysis.com/quote/etr/GXI/transcripts/397265-q4-2025/)

Executive talk · Uwe Röhrhoff, Interim CEO · 2026-06-29

- First call in months, held the day the audited 2025 accounts came out: interim CEO Uwe Röhrhoff said the new board's focus "right from day one, has been on governance, cleaning up, and driving transformation"; all bill-and-hold and forensic investigations are completed and booked.
- Restatement: 2024 revenue -2% or EUR 45 million, EBITDA -7% or EUR 31 million; impairments EUR 258 million (guided EUR 220-240 million), mainly Sensile Medical projects and the Chicago plant.
- 2025: revenue EUR 2.3 billion, organic +0.3%; adjusted EBITDA margin 16.8% (currency-adjusted); Plastics and Devices organic +5%, Primary Packaging Glass about 6% lower; Röhrhoff: "Clearly, PPG performance is not at an acceptable level."
- Two "must-dos" from the auditor's emphasis of matter: sell Centor and refinance the debt (Lazard mandated); leverage 4.95x, covenant suspended to Q3 2026.
- 2026 guidance: revenue in the lower half of EUR 2.3-2.4 billion, margin about 17%-18%, free cash flow EUR -50 to -100 million, mostly because of reduced (reverse) factoring.
- GTO transformation (with BCG and Verto) refocused on fast payback: EUR 10-20 million EBITDA this year (50-100 bps), five workstreams, running into 2028.
- New segments: Containment & Delivery Systems about 50% of sales (a bit over 40% after Centor), Primary Injectable Solutions about 20%, Moulded Glass run standalone under new BU CEO Daniel Winkler, divestiture timing undecided.

### [Preliminary Q2 2026 results earnings call (transcript)](https://stockanalysis.com/quote/etr/GXI/transcripts/397268-q2-2026-tu/)

Executive talk · Achim Schalk, Member of the Management Board · 2026-09-30

- Q2 2026 (March-May) preliminary: revenue EUR 578 million (prior year EUR 614 million); adjusted EBITDA EUR 102 million, up more than 50% from Q1's EUR 67 million; free cash flow before M&A EUR -92 million on lost reverse-factoring lines.
- Centor and Primary Packaging Plastics sales signed end of July at a combined enterprise value of around EUR 1.5 billion; Lehmann: "This truly marks an inflection point for Gerresheimer, as this solves our too-high-debt burden." Target leverage at or below 3x.
- Grow / fix / sell portfolio: grow Medical Device Systems, Syringe Systems and Tubular Glass North America; fix Tubular Glass Europe and SG&A (more than 20% SG&A cost cut into 2027); "fix to sell" Moulded Glass.
- GTO targets EUR 50-70 million EBITDA improvement by end-2027, full benefit in 2028; Chicago Heights furnace shut down the day before the call.
- Containment & Delivery Systems Q2 revenue EUR 308 million, EBITDA EUR 74 million (nearly 24% margin) on the Peachtree City ramp-up; Moulded Glass EBITDA tripled from EUR 8 million to EUR 25 million.
- Schalk's aspiration for the new Gerresheimer: "to get in reach of the 20% EBITDA and targeting a 2x GDP growth rate"; GLP-1 franchise backed by take-or-pay contracts.
- Energy over 75% hedged in 2026, less than 50% for next year; net debt slightly above EUR 2 billion, liquidity EUR 249 million.

### [Preliminary Q3 2026 results earnings call (transcript)](https://stockanalysis.com/quote/etr/GXI/transcripts/651752-q3-2026-tu/)

Executive talk · Wolf Lehmann, CFO · 2026-10-30

- Q3 2026 preliminary: revenue EUR 605 million (+EUR 46 million), adjusted EBITDA EUR 103 million, free cash flow before M&A EUR -20 million; inventory cut by EUR 20 million versus a EUR 14 million build a year earlier.
- Centor closed on October 1, two months after signing; about 90% of gross proceeds go to debt, repaying close to EUR 700 million by year-end; PPP closing now expected in Q1 2027; leverage to fall to around 3x and gross debt from a bit under EUR 2.3 billion to below EUR 0.9 billion.
- Guidance kept: revenue EUR 2.3-2.35 billion, organic margin 17%-18%, free cash flow EUR -50 to -100 million; needs around EUR 120 million of Q4 EBITDA, which Lehmann says the company has visibility to.
- Peachtree revenue expected to more than double in FY2026 to a triple-digit million euro level; GLP-1 "in the ballpark" of the EUR 350 million target.
- Tubular Glass Europe and Moulded Glass remain the problems; Moulded Glass runs at EUR 80-85 million annualized EBITDA, ambition EUR 100 million and beyond, no sale date.
- Lehmann and Schalk lead as "co-CEOs" pending a permanent CEO; BaFin investigation ongoing with no timeline.
- 2027: higher energy costs a headwind (under 50% hedged); capex about 9% of sales in 2026 (EUR 149 million in nine months, 37% lower).

## Questions about Gerresheimer

### What does Gerresheimer do?

Gerresheimer makes drug containment and delivery products for pharma, biotech and cosmetics customers, including syringes, pens, auto-injectors, inhalers, vials, cartridges, ampoules and glass and plastic bottles.

### What is Gerresheimer's revenue?

FY2025 revenues were EUR 2,320.9m with adjusted EBITDA of EUR 384.0m. For FY2026 the company guides to revenue of EUR 2.3-2.35 billion.

### How many employees does Gerresheimer have?

About 13,600 people at November 30, 2025, with companies consolidated from 17 countries.

### Who leads Gerresheimer?

CFO Wolf Lehmann and Management Board member Achim Schalk lead as co-CEOs while the Supervisory Board decides on a permanent CEO; Uwe Röhrhoff was interim CEO from November 1, 2025.

### What is Gerresheimer's strategy?

A grow, fix and sell portfolio strategy: grow drug delivery devices and syringes, fix Tubular Glass Europe and SG&A through the gto transformation, sell Centor and Primary Packaging Plastics to cut debt, and later divest Moulded Glass.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
